Expanding the Potential of TCR-Based T-Cell Engagers into Infectious Diseases

• Sharing early clinical data on TCR-based bispecific molecules developed to treat HBV and HIV
• Analyzing the pharmacokinetics and pharmacodynamics associated with this mechanism of action
• Highlighting the differences from oncology that emerge due to a lack of suppressive tumor microenvironment

New Data

Speakers:

Annelise vuidepot

Senior Vice President, Chief Science & Technology Officer

Immunocore